Tymlos (abaloparatide)

What is Tymlos (abaloparatide) for?

Tymlos (abaloparatide) is a human parathyroid hormone-related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture^[1].

How does Tymlos (abaloparatide) work?

Abaloparatide is a PTHrP(1-34) analogue which acts as an agonist at the PTH1 receptor (PTH1R)1.

In bone, the PTH1R is expressed on the surface of osteoblasts^[2], the cells that synthesize bone^[3]. By attaching to these receptors abaloparatide activates important processes in target cells, which are expected to stimulate the increase of bone’s density and strength.

Where has Tymlos (abaloparatide) been approved?

Tymlos (abaloparatide) was approved for the treatment of patients with osteoporosis at high risk for fracture by:

• Food and Drug Administration (FDA), USA, April 28, 2017^[1].

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Tymlos (abaloparatide) taken?

The standard dosage is:

• 80 mcg subcutaneous injection once daily into periumbilical region of the abdomen.

Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.

Warning:

• Use of Tymlos is not recommended in patients at increased risk for osteosarcoma.
• Cumulative use of Tymlos and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.

Complete information about Tymlos (abaloparatide) dosage and administration can be found in the official prescribing information listed in our references section^[1].

Note: Please consult with your treating doctor for personalised dosing.

Are there any known side effects of Tymlos (abaloparatide)?

Common side effects

The most common side effects listed in the prescribing information include^[1]:

• hypercalciuria (elevated calcium in the urine)
• dizziness
• nausea
• headache
• palpitations
• fatigue
• upper abdominal pain
• vertigo.

Serious side effects

The serious side effects listed in the prescribing information include^[1]:

• Orthostatic Hypotension
• Hypercalcemia
• Hypercalciuria and Urolithiasis.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information^[1].

References

1. Summary of Product Characteristics [FDA]: Tymlos (abaloparatide) [PDF]
Radius Health Inc., Apr. 2017.

2. Wikipedia. Parathyroid hormone 1 receptor
cited June 2017

3. Wikipedia. Osteoblast
cited June 2016

4. Drugs.com. FDA Approves Tymlos
April 2017